H.C. Wainwright lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $9 from $20 and keeps a Buy rating on the shares ahead of the Q3 report on November 6. The firm believes Iovance “is squarely in the investor’s penalty box.” It remains positive on the shares but believes the company is in a “show-me” stage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study
- Iovance Biotherapeutics’ Phase 3 Study: A Potential Game-Changer in Melanoma Treatment
- Iovance Biotherapeutics Advances TIL Therapy in Pediatric Cancer Study
- Iovance Biotherapeutics’ Promising Phase 2 Study on LN-145 for Lung Cancer
- Iovance Biotherapeutics’ Innovative Cancer Study: A Potential Game-Changer?